Aβ₄₂ Fibrillogenesis Inhibitor III - Calbiochem

A modified analog of Aβ₄₂ Fibrillogenesis Inhibitor I (Cat. No. 171586) that crosses the blood-brain barrier and acts as a β-sheet breaker. Reported to increase neuronal survival and reduce brain inflammation in a transgenic mouse model of Alzheimer’s disease, probably due to a reduction in Aβ deposits. Displays greater stability against proteolytic degradation (t_1/2 >24 hours in human plasma and cerebrospinal fluid; ~ 37 minutes in blood).

A modified analog of Aβ₄₂ Fibrillogenesis Inhibitor I (Cat. No. 171586) that crosses the blood/brain barrier and acts as a β-sheet breaker. Increases neuronal survival with a concomitant reduction in brain inflammation by inducing a dramatic reduction in Aβ deposition in a transgenic mouse model of Alzheimer′s disease. Displays greater stability against proteolytic degradation (t_½ >24 h in human plasma and cerebrospinal fluid; ~37 min in blood).

Cell permeable: no

Primary Target
Reduction in Aβ deposits

Product does not compete with ATP.

Reversible: no

Packaged under inert gas

Following reconstitution aliquot and freeze (-20°C). Stock solutions in DMSO are stable for up to 6 months at -20°C. Stock solutions in H₂O are stable for up to 1 month at -20°C.

Ac-Leu-Pro-Phe-Phe-Asp-NH₂

Permanne, B., et al. 2002. FASEB J.16, 860.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)